Pharma & lifesciences

Pharma & lifesciences

In the context of criminal proceedings concerning the potential violation of the legal requirements applicable to...
The term “industrial scale” appears twice in the draft EU Medical Devices Regulation (“MD Regulation”) in...
The EU’s regulatory framework for orphan drugs is set out in Regulation (EC) No.141/2000 (the “Orphan...
Bristows’ Biotech Review, a publication looking at many of the key developments in this area in...
In October 2014, the Nagoya Protocol entered into force. It created a new international regulatory system affecting...
Two important developments occurred in mid-November 2016 for the pharmaceutical industry in Europe: the European Commission...
On 10 November 2016, the European Union Court of Justice (ECJ) rendered a judgment regarding the...
Onlangs heeft het Hof van Justitie de Duitse wet die bepaalt dat apotheken receptplichtige geneesmiddelen voor...
As the healthcare industry continues to embrace the Internet of Things, cybersecurity may present unprecedented health...
‘In 2016 users will trust health apps more than their doctors’. So predicted Forbes Magazine in...
The decision as to which model will be adopted by the UK and the EU post-Brexit...
The Access to Medicine Index analyses the top 20 research-based pharmaceutical companies on how they make medicines, vaccines...
On 8 November 2016, the European Commission published the opinion of the European Medicines Agency (EMA)’s...
La «Convention Medicrime», de son nom complet «Convention du Conseil de l’Europe sur la contrefaçon des...
On October 19, 2016, the Court of Justice of the European Union (CJEU) issued a landmark...
Conclusie 20 oktober 2016. Advocaat-generaal Mengozzi concludeert dat het niet in strijd met het EU-recht is...